Trading Analysis Report: BILI

• Analysis date: 2026-10-03
• Rating: Underweight
• Generated: 2026-10-04 19:06:04
• TradingAgents 0.6.0: openai, deep gpt-6-sol, quick gpt-6-sol
• Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
• Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports

Market Analyst

Current Price: $14.44 Price As Of: 2026-10-02

BILI technical outlook

BILI’s weekly and daily trends remain bearish, although its monthly SuperTrend still points up. The weekly signal takes priority in this framework. At the same time, a completed monthly TD-9 buy setup and a weekly count nearing nine make selling exhaustion worth watching. They do not, by themselves, confirm a reversal. October 3 is a Saturday, so the October 2 close is the latest available bar.

Price and trend. BILI closed below its falling 50-day SMA of $16.53. That average stood near $17.50 on September 4, so the medium-term benchmark has continued to decline. Recent price action is also fragile: BILI closed at $14.40 on September 17 and $14.44 on October 2. The October 2 intraday low of $14.31 was below September 17’s $14.39 low. Those are observable reference prices, not established support.

The three SuperTrend tiers explain the conflicting horizons:

• Weekly, primary: DOWN, with a trailing line at $19.77.
• Monthly, regime context: UP, with a trailing line at $13.37.
• Daily, entry timing: DOWN, with a trailing line at $15.82.

Thus, the monthly uptrend has not flipped, but BILI is trading below both the daily and higher-priority weekly lines. The daily line is a nearer reversal test than the weekly line; neither should be treated as a fixed future price because the indicators can move.

Momentum and participation. RSI is 36.98—weak, but not below the conventional 30 oversold threshold. The MACD histogram remains slightly positive at 0.03, yet has narrowed from approximately 0.057 on October 1. That suggests the recent improvement in momentum is fading even while the histogram remains positive; it is not enough to override the bearish trend readings. OBV has declined overall from 136,696,900 on September 8 to 128,329,800 on October 2, alongside closes of $16.20 and $14.44 on those dates. Its path was not uniformly downward, but participation does not yet provide convincing confirmation of a sustained rebound. OBV’s direction, not its absolute level, matters here.

Exhaustion versus confirmation. TD-9 reports a weekly +8, a monthly completed +9, and a daily +2 buy setup. The monthly completion raises a reversal watch, while the weekly count suggests exhaustion may be approaching; the daily count offers no completed setup. Z-scores are −1.90 weekly, −1.38 monthly, and −1.56 daily. All indicate prices below their respective 20-period means, but none reaches the −2 stretch threshold. These readings justify watching for a countertrend move, not assuming one has begun. The October monthly readings are based on a month that has not finished and can change.

Actionable levels and risk

• For a BILI rebound setup: Look for a close back above the then-current daily SuperTrend line, currently $15.82, followed by evidence of stronger OBV and momentum. A sustained reclaim of the $16.53 50-day SMA would provide a more demanding medium-term confirmation. RSI moving toward or above 50 would add support.
• For BILI downside continuation: A close below the $14.31 October 2 low, particularly with falling OBV, would strengthen the breakdown case. The monthly SuperTrend line, currently $13.37, is a lower regime-risk reference; a close through the applicable line would threaten the remaining monthly uptrend. Neither level is a guaranteed stopping point.
• For position sizing: ATR is $0.46. A stop placed just below $14.31 from the $14.44 close allows less than one ATR of room, so ordinary volatility could trigger it. Size any position against its actual entry-to-stop distance, and allow for gaps and slippage. Indicator lines and ATR should be recalculated when a setup occurs.

Bottom line: BILI has a credible exhaustion watch, but the evidence still favors treating a bounce as countertrend until price, momentum, and volume confirm otherwise.

Key point	Latest evidence	Trading implication
Price references	Close $14.44; October 2 low $14.31; September 17 close $14.40	Watch for a confirmed close below the recent low; do not presume these prices are proven support.
SuperTrend	Weekly DOWN / $19.77; monthly UP / $13.37; daily DOWN / $15.82	Weekly bearish signal takes priority; a daily reclaim would be an initial, not definitive, improvement.
50-day SMA	$16.53, above price and falling	Sustained recovery above it would strengthen the medium-term case.
RSI	36.98	Weak momentum, but no conventional sub-30 oversold signal.
MACD histogram	+0.03, narrowing	Modest positive impulse is fading; seek renewed expansion for a rebound.
ATR	$0.46	Use volatility-aware stops and position sizes.
OBV	Lower on October 2 than September 8	Participation has not confirmed a durable recovery.
TD-9	Weekly +8; monthly +9 complete; daily +2	Watch for exhaustion, while requiring price confirmation.
Z-score	Weekly −1.90; monthly −1.38; daily −1.56	Below-mean pricing, but no tier is at the ±2 stretch threshold.

Sentiment Analyst

Overall Sentiment: Mildly Bearish (Score: 4.0/10) Confidence: Low

BILI sentiment | 2026-09-26 to 2026-10-03

Source-by-source evidence

1. Yahoo Finance news (one headline): MT Newswires reports that Asian equities traded in the US as ADRs started the week lower. This is a mildly negative regional/ADR backdrop, not evidence that BILI itself fell or that Bilibili Inc. announced a company-specific development. The supplied headline gives no BILI price move, earnings update, or identifiable company catalyst.
2. StockTwits (three most-recent messages): User tags are 0 bullish, 0 bearish, and 3 unlabeled. There is therefore no measurable tagged bullish/bearish ratio; 0/0 should not be read as balanced sentiment. The Oct. 2 post describing a "$BILI crowded breakdown" and a "slide" is an explicitly negative trader characterization, not a verified chart signal. Its 13,856-watchers figure is not a count of bearish participants. Another Oct. 2 message, "$BILI fBILI and the Chinese market," conveys frustration but offers no factual catalyst. The Sep. 28 watchlist post says Bilibili adds exposure to "video, adv…"; it is truncated and at most a tentative constructive or descriptive counterpoint. Its detailed trading-volume figures concern HUYA, not BILI, and cannot be attributed to BILI.
3. Reddit: Collection was disabled by configuration. No r/wallstreetbets, r/stocks, or r/investing posts are available to assess; absence of posts here is not evidence of absent discussion or neutral sentiment.

Cross-source alignment and divergence

The broad negative ADR headline and two cautionary/frustrated StockTwits remarks lean in the same direction, but they do not independently establish a BILI-specific decline. The truncated watchlist mention supplies a weak possible counterpoint, not a clear bullish-versus-bearish cross-source divergence. The unlabeled StockTwits tags and missing Reddit feed materially limit confidence.

Dominant narrative, potential catalysts, and risks

The observable narrative is concern about Chinese-market/ADR weakness and a perceived BILI breakdown. Regional ADR performance could remain a sentiment catalyst; whether BILI actually confirms the alleged breakdown would require price and volume data not supplied here. No BILI-specific earnings, product, regulatory, or other dated catalyst appears in the provided material. Key interpretive risks are treating a regional headline as a BILI-specific event, treating watchers as votes, mistaking HUYA statistics for BILI statistics, or projecting a price move from three social posts. This is a low-confidence, mildly bearish sentiment snapshot for another agent to weigh alongside fundamentals and verified technicals, not a trade decision or price forecast; the supplied tools support a structured sentiment report, not independent market-data verification or trade execution.

Sentiment signal	Direction	Source	Supporting evidence and limits
Asian ADRs started week lower	Mildly bearish backdrop	Yahoo Finance / MT Newswires	One regional headline; does not establish a BILI-specific move.
Claimed crowded breakdown/slide	Bearish opinion	StockTwits, Oct. 2	One unlabeled BILI message; no chart data supplied to verify it.
Frustration with BILI and Chinese market	Bearish-leaning, ambiguous	StockTwits, Oct. 2	One unlabeled short remark; no factual company event.
Video/advertising exposure mention	Neutral to tentatively constructive	StockTwits, Sep. 28	Truncated BILI excerpt in a watchlist; HUYA metrics elsewhere in the post are not BILI metrics.
Tagged stance and community corroboration	Unavailable	StockTwits / Reddit	0 bullish, 0 bearish, 3 unlabeled; Reddit collection disabled.

News Analyst

BILI trading and macro briefing — October 3, 2026

Bottom line: The past week’s available news does not establish a new BILI-specific operating catalyst. The clearest near-term influences are the broader market’s response to U.S. interest-rate expectations and unresolved questions around BILI’s September financing. I would treat a move in BILI as a market move until it is supported by company-specific news or sustained relative strength.

What changed this week

The BILI news feed for September 26–October 3 returned one report that Asian equities trading as U.S. depositary receipts started Monday lower. Its headline does not establish BILI’s individual return. The feed showed no new BILI earnings, advertising, gaming or regulatory announcement in that period.

U.S. markets finished the week on a different note. October 2 coverage reported a stock and technology rally as expectations of a Fed rate hike faded; separate coverage linked the move to a weaker-than-expected jobs report and easing Treasury yields. Lower yields can support growth-stock valuations, including BILI’s, but a weakening economy can also hurt advertisers. That tension matters more than the rally headline alone.

Inflation remains a counter-risk. Coverage of Iran-related conflict argues that price pressures extend beyond oil, while Moody’s economist Mark Zandi warned about the damage from higher rates. These are reported assessments, not verified inflation or growth readings for this briefing. For BILI, the principal channel is a change in discount rates and risk appetite, rather than direct energy exposure.

BILI-specific items still worth pricing in

In early September, company-release headlines described a US$700 million convertible-note proposal and pricing, with an equity placement and share repurchases. Another release described completion of a US$500 million marketed convertible-note offering, concurrent equity placement and delta repurchase. Do not add those headline amounts together or assume their net dilution: the available headlines do not reconcile the transactions. Confirm the offering documents, conversion terms, net proceeds and repurchase effects before changing a per-share valuation.

BILI has also announced an extraordinary general meeting for October 28. Its agenda, rather than the meeting date alone, is the potential catalyst. BNP Paribas initiated coverage at Outperform with a $23 target in September; without a verified current BILI price, that target cannot be translated into implied upside.

Trading plan for the next session

• Conditional bullish case: If falling Treasury yields accompany strength across China-related U.S. shares and BILI shows sustained relative strength on meaningful volume, consider a risk-sized entry rather than buying solely on the October 2 U.S. tech rally.
• Caution case: If yields or the dollar rise on renewed inflation concerns, or BILI lags its peer group, avoid chasing a broad-market bounce. Review the financing documents before treating a sharp move as evidence of improved fundamentals.
• Company checks: Watch for verified updates to advertising revenue, user engagement, game monetization, margins and cash flow, alongside the October 28 meeting agenda. No fresh figures for these measures were available in the past-week feed.

Data limits: FRED requests for policy rates, Treasury yields, inflation, unemployment, volatility and USD/CNY returned access errors. Prediction-market odds were withheld because the available live markets could not be reliably dated to October 3. Accordingly, this report makes no numerical macro, currency, market-odds or BILI-price claim.

Driver	Evidence available as of October 3	BILI implication / trader check
Company news this week	Only a broad Asian-ADR trading headline; no verified new operating announcement in the feed	Do not infer a BILI-specific trend from the ADR headline
U.S. rates and employment	October 2 reports: jobs disappointment, easing yields and tech gains	Watch whether lower yields support BILI without worsening growth fears dominating
Inflation risk	Reporting raised concern about conflict-related price pressure	Rising yields could reverse growth-stock support
September financing	Headlines cite US$700m pricing and a US$500m completion; terms not reconciled here	Verify filings, dilution and repurchase effects before revising valuation
October 28 meeting	BILI announced an extraordinary general meeting	Read the agenda for a concrete catalyst; do not trade on the date alone
Decision quality	No verified current BILI price, FRED observations or dated prediction-market odds	Use current quotes and filings to set entries and risk limits; avoid invented price targets

Fundamentals Analyst

BILI — fundamental report

As of October 3, 2026 | Bilibili Inc. | NMS | Communication Services / Internet Content & Information

Bottom line: BILI’s latest available in the supplied financial-statement data annual results show a substantial turnaround: 2025 revenue grew, operating income became positive, and operating cash flow remained strong. The principal counterweight is a faster rise in liabilities than in assets or cash, alongside a large investing cash outflow. These data do not establish what changed during the past week or how BILI is performing in 2026.

Scope and company profile

BILI is Bilibili Inc., a China-focused online video and community business. Advertising, value-added services, games, and other content-related activities are relevant business lines to examine, but the available tools do not supply a current segment breakdown, operating metrics, management guidance, or a verified current company profile beyond the identity and classification above.

The statement figures below are SEC EDGAR facts reported by the vendor as filed by October 3, 2026. Although some tool headers say “USD in millions,” the individual data rows explicitly say CNY and contain full currency amounts; this report converts them to CNY billions. No exchange-rate conversion has been made.

Past-week limitation: The tools do not provide a filing log or document dates sufficient to verify announcements between September 26 and October 3, 2026. A lack of a verified update here must not be read as proof that BILI issued none. The fundamentals and insider-transaction feeds are withheld for this point-in-time date, so current market capitalization, valuation multiples, share price, and recent insider buying or selling cannot be assessed.

Earnings and financial history

Fiscal year	Revenue, CNY bn	Gross margin	Operating income, CNY bn	Net income, CNY bn	Operating cash flow, CNY bn	Free cash flow*, CNY bn
2021	19.384	20.9%	−6.429	Not tagged	−2.647	−3.612
2022	21.899	17.6%	−8.358	Not tagged	−3.911	−4.672
2023	22.528	24.2%	−5.064	−4.822	0.267	0.085
2024	26.832	32.7%	−1.344	−1.347	6.015	5.549
2025	30.348	36.6%	1.124	1.194	7.147	6.634

*Free cash flow here means operating cash flow less the vendor’s reported capital expenditure. “Not tagged” is a data-availability limitation, not a zero or an assertion that BILI was profitable.

In 2025, revenue rose 13.1% from 2024, while cost of revenue rose about 6.5%. Gross profit consequently increased from CNY 8.774 billion to CNY 11.114 billion, lifting gross margin by approximately 3.9 percentage points. Operating income swung by CNY 2.468 billion, from a loss to a CNY 1.124 billion profit; the resulting operating margin was about 3.7%, versus −5.0% in 2024. Net income swung by CNY 2.540 billion to CNY 1.194 billion. Reported diluted EPS moved from −CNY 3.23 in 2024 to CNY 2.74 in 2025; investors should verify the applicable per-share/ADS convention before comparing that figure with BILI’s quoted security.

The longer record puts the turnaround in perspective: annual operating income was negative in every available year from 2016 through 2024, with the largest loss in this recent five-year table occurring in 2022. The supplied “quarterly” income and cash-flow extracts do not offer a usable 2026 comparison—their only interim income and cash-flow entries are nine-month periods in 2021 and 2022. Traders should obtain BILI’s actual 2026 interim releases before treating the 2025 improvement as a continuing trend.

Balance sheet and liquidity

At December 31, 2025, BILI reported CNY 41.168 billion of assets, CNY 25.619 billion of liabilities, and CNY 15.573 billion of stockholders’ equity. Cash and equivalents were CNY 12.184 billion, up from CNY 10.249 billion a year earlier. Current assets of CNY 27.550 billion exceeded current liabilities of CNY 20.327 billion by CNY 7.223 billion; the current ratio was approximately 1.36, versus 1.34 at year-end 2024.

The less favorable comparison is the pace of balance-sheet growth: total liabilities increased about 37.8% in 2025, versus 25.9% for assets and 18.9% for cash. Liabilities rose to about 62.2% of assets, from 56.9% in 2024. Cash covered about 60% of current liabilities, down from 69%. These are reasons to inspect the composition and maturity of the added liabilities. The available extract does not break out debt, so net debt or a debt-maturity conclusion cannot be calculated responsibly.

Cash-flow quality and financing

BILI generated CNY 7.147 billion of operating cash flow in 2025, up 18.8% from 2024. After CNY 0.513 billion of reported capital expenditure, the defined free-cash-flow measure above was CNY 6.634 billion, up 19.5%. Positive operating cash flow is an important confirmation of the earnings turnaround, although the large difference between operating cash flow and CNY 1.194 billion of net income warrants review in the full cash-flow notes for working-capital and noncash contributors.

Investment and financing flows tell a more cautious story. Investing cash flow was −CNY 9.341 billion in 2025, compared with −CNY 0.138 billion in 2024. Operating cash flow did not cover that total investing outflow: the two combined were −CNY 2.194 billion. Financing cash flow was +CNY 4.087 billion, versus −CNY 2.825 billion in 2024. The supplied totals do not identify what drove the investing outflow or financing inflow; traders should not assume either was ordinary capital spending, borrowing, or an equity issuance without the underlying disclosures.

Trading implications

• Constructive case: BILI’s 2025 improvement has support from both reported operating profit and cash generation. Before taking a position on that thesis, check the newest 2026 results for a still-positive operating margin and operating cash flow; 2025’s 3.7% operating margin and CNY 7.147 billion annual operating cash flow are historical benchmarks, not 2026 forecasts.
• Key deterioration signals: A gross margin returning toward 2024’s 32.7% from 2025’s 36.6%, a renewed operating loss, or liabilities continuing to grow substantially faster than cash would weaken the turnaround case.
• Required due diligence before a trade: Obtain the most recent 2026 company filing or release, identify the CNY 9.341 billion 2025 investing outflow and CNY 4.087 billion financing inflow, check liability maturities, and compare an up-to-date BILI price with a current valuation. The supplied tools cannot support a price target, an entry level, or an insider-sentiment claim.

Key point for BILI	Evidence available as of October 3, 2026	Trader’s use
Profitability turnaround	2025 operating profit CNY 1.124bn, versus 2024 loss CNY 1.344bn	Verify that 2026 results sustain positive margins.
Revenue and gross-margin gains	2025 revenue +13.1%; gross margin 36.6%, versus 32.7%	Watch whether monetization outpaces cost of revenue.
Strong operating cash generation	2025 operating cash flow CNY 7.147bn; defined FCF CNY 6.634bn	Check cash-flow drivers and repeatability in newer filings.
Rising balance-sheet obligations	2025 liabilities +37.8%; cash/current liabilities fell to about 60%	Examine debt, payables, and maturity details before sizing risk.
Investing and financing uncertainty	2025 investing cash flow −CNY 9.341bn; financing cash flow +CNY 4.087bn	Resolve the underlying transactions; do not infer their nature from totals.
Past-week and market-data gap	No verifiable past-week filing log, current valuation, or point-in-time insider feed	Do not trade as though this report confirms a new weekly catalyst or current price-based value.

II. Research Team Decision

Bull Researcher

Bull Analyst: My opening case for BILI is a fundamental turnaround, not a call that the chart has already turned. At the October 2 close of $14.44, the strongest reason to be constructive is that Bilibili’s latest available annual results show growth translating into profit and cash—not just a larger audience-facing business with persistent losses.

BILI’s 2025 revenue rose 13.1% to CNY 30.348 billion, while gross margin expanded from 32.7% to 36.6%. Operating income swung from a CNY 1.344 billion loss to a CNY 1.124 billion profit, and operating cash flow reached CNY 7.147 billion. That combination is the bull case in miniature: revenue grew, delivery costs grew more slowly, and the improvement reached the bottom line. BILI’s video-and-community model has several potential monetization routes—including advertising, value-added services and games—so further revenue growth could benefit from the operating leverage demonstrated in 2025. As an illustration, repeating 2025’s 13.1% growth would put annual revenue near CNY 34.3 billion; that is a scenario, not a 2026 forecast or company guidance.

I expect the bear to lead with the falling price, and that objection is fair. BILI is below its $15.82 daily SuperTrend line and $16.53 50-day average, while the weekly trend remains down. I would not call the completed monthly TD-9 buy setup a reversal signal. But weak trading does not erase a profitable year, and the mildly bearish social-media reading rests on only a few unlabeled posts and a regional ADR headline—not a verified deterioration in BILI’s operations. September’s BNP Paribas $23 Outperform target is another constructive opinion, though it is no substitute for our own valuation.

The more serious bear challenge is financial: 2025 liabilities rose 37.8%, and operating cash flow did not cover the CNY 9.341 billion total investing outflow. Those figures need explaining, as do September’s convertible financing terms; I would not assume repurchases cancel potential dilution. Still, BILI ended 2025 with CNY 12.184 billion in cash and CNY 7.223 billion more current assets than current liabilities. That gives the turnaround a liquidity base while investors investigate those risks.

My stance is constructive on BILI, but selective on entry. I want current 2026 results to confirm that positive margins and cash generation persist. A reclaim of the daily trend line, then the 50-day average, would make the market case stronger; a break below the $14.31 recent low would argue for patience. Bear, the chart says “prove it”—I agree. The 2025 operating results give BILI a credible chance to do exactly that. Bull Analyst: Bear, your strongest point is that BILI’s 2025 turnaround has not yet been verified in the supplied 2026 financial data. I would not pay for guaranteed durability. But I also would not treat uncertainty as a reason to ignore what changed: BILI grew 2025 revenue 13.1%, expanded gross margin from 32.7% to 36.6%, and moved from a CNY 1.344 billion operating loss to a CNY 1.124 billion profit. Operating cash flow reached CNY 7.147 billion. That is a substantially stronger starting position than the loss-making business investors faced a year earlier.

Your margin calculation is fair—but it holds revenue constant. BILI’s advertising, value-added services, and games give its video community several potential routes to grow revenue, though we lack current segment and engagement figures to prove their progress. To illustrate the operating leverage, if revenue repeated 2025’s 13.1% growth and gross margin fell all the way back to 32.7%, revenue would be about CNY 34.3 billion and operating profit about CNY 1.2 billion, assuming 2025 operating expenses stayed roughly flat. That is a scenario, not guidance. If growth stalls or expenses rise, your thin-margin concern wins; if monetization continues, a margin setback need not erase profitability.

I agree that CNY 6.634 billion of capex-adjusted free cash flow is not cash left after all investing. Operating cash flow fell CNY 2.194 billion short of total investing outflows, and we need to identify those transactions. Still, BILI had CNY 12.184 billion of cash and a CNY 7.223 billion current-asset surplus at year-end 2025. Those figures do not resolve faster-growing liabilities or September’s unreconciled financing terms, but they do give the company liquidity while we investigate them. I would not assume the repurchases cancel dilution or use the bank’s $23 target as my valuation.

The chart also argues for restraint, not surrender. At the October 2 close of $14.44, BILI remained below the $15.82 daily trend line and $16.53 50-day average, with the weekly trend down. The monthly uptrend and exhaustion setup make a turn worth watching, not confirmed.

So my conclusion differs from yours on position size, not on diligence: I favor a small, staged BILI investment for a long-horizon investor who can tolerate the unresolved risks, rather than a full allocation or an unconditional wait. I would add only after reviewing 2026 margins, cash flow, and financing terms—and preferably seeing price reclaim those trend levels with stronger participation. A close below $14.31, or evidence that profitability has reversed, would force a reassessment. Bull Analyst: Bear, I agree that a smaller BILI position does not resolve the missing 2026 results or the financing questions. It does something different: it limits what an investor risks while testing whether the 2025 turnaround persists. Waiting for proof is a defensible choice; I think a long-horizon investor can also justify a small, explicitly speculative starter position.

Your margin stress test is useful, but it combines two setbacks: gross margin falling from 36.6% to 32.7% and the costs between gross and operating profit rising roughly 12%. Neither is impossible. Neither describes what happened in 2025: gross profit rose about CNY 2.34 billion, while those costs fell roughly CNY 0.13 billion, producing the CNY 2.47 billion operating-income swing. That is evidence BILI achieved operating leverage, though not proof it will repeat it.

The upside sensitivity matters alongside yours. If revenue again grew 13.1% and gross margin held near 36.6%, illustrative operating profit would be about CNY 2.6 billion with those costs flat—or about CNY 1.4 billion even if they rose 12%. Those are scenarios, not 2026 estimates. They show why I would not make a return to near-zero profit the default simply because it is possible. We need current advertising, services, games and engagement data to judge which path is more credible; I am not claiming BILI has a proven moat from the figures supplied.

On cash, I accept your distinction completely. CNY 6.634 billion is operating cash flow less reported capex, not cash remaining after all investing. The CNY 2.194 billion gap between operating cash flow and total investing outflows, faster-growing liabilities, and September’s unreconciled financing terms are reasons to cap exposure—not reasons to discard the CNY 12.184 billion year-end cash balance or the demonstrated operating cash generation. I would not claim a per-share bargain without current valuation and dilution data.

Nor am I calling the chart bullish. BILI closed at $14.44 on October 2, below the $15.82 daily trend line and $16.53 50-day average. A close below $14.31 would prompt reassessment, not an automatic stop placed just cents away in a stock with $0.46 ATR. I would add only if 2026 margins and cash flow hold up, financing becomes clearer, and price participation improves.

So the disagreement is about when to take limited risk, not whether proof matters. I favor a small, risk-sized BILI starter position; you favor waiting for confirmation. The 2025 profit-and-cash turnaround makes that early exposure reasonable to me, while the unresolved 2026 evidence makes a full-sized position premature. Bull Analyst: Bear, the reason I would buy a small BILI position at the last available close of $14.44 is not that I can prove it is cheap—we lack a current per-share valuation and reconciled financing terms. It is that the operating transition is already more than a one-quarter promise. BILI moved from a CNY 1.344 billion operating loss in 2024 to a CNY 1.124 billion profit in 2025, while operating cash flow rose from CNY 6.015 billion to CNY 7.147 billion. I would take limited exposure to the possibility that this transition persists, then require 2026 evidence before committing more.

Your sensitivity test is fair, but its result matters: even with 13.1% revenue growth, a one-percentage-point gross-margin decline, and a 12% rise in costs between gross and operating profit, BILI would still generate roughly CNY 1.0 billion in illustrative operating profit. That would disappoint anyone expecting rapid earnings growth; it would not return BILI to its years of operating losses. Nor should we make the 12% cost increase our default assumption when those costs fell slightly in 2025. BILI’s video community can potentially support advertising, services and games on the same platform; the gross-margin improvement offers evidence of scalability, though the missing segment and engagement data prevent me from claiming a proven moat.

I take your balance-sheet objection seriously. CNY 6.634 billion of operating cash flow less reported capex is not cash left after all investing. The CNY 9.341 billion investing outflow, faster-growing liabilities and September financing need explanation. The counterweight is tangible liquidity: CNY 12.184 billion in cash and a CNY 7.223 billion current-asset surplus at year-end 2025. That supports a limited-risk thesis, not an unqualified per-share upside claim.

And I would not call the chart a buy signal. BILI remains below the daily trend line and 50-day average, with weak OBV. A close below $14.31 would prompt review, not a mechanical stop just cents below price when ATR is $0.46.

So we differ on the cost of waiting. My BILI recommendation is a small, speculative starter position for a risk-tolerant, long-horizon investor—not a full allocation. I would add only if 2026 margins and cash flow hold up, the financing is clarified, and price strength gains participation. If those tests fail, your wait-and-see position will have been the better one. Bull Analyst: Bear, your 5% growth scenario is the right stress test for BILI. It shows that the CNY 1.124 billion operating profit earned in 2025 is not a large cushion if growth slows and costs rise. I would not present 2025 operating cash flow as proof otherwise: BILI generated substantial cash from operations in 2024 while still reporting an operating loss.

But your CNY 0.15 billion profit scenario combines three setbacks: growth slowing from 13.1% to 5%, gross margin slipping one percentage point, and costs between gross and operating profit rising 12%. Hold those costs at their 2025 level under your same 5% growth and 35.6% gross-margin assumptions, and illustrative operating profit is about CNY 1.35 billion. Neither outcome is a forecast. The reason I give cost discipline a chance is observable: those costs fell by roughly CNY 0.13 billion in 2025, while revenue grew and gross margin improved. BILI has demonstrated operating leverage for one year, even though it has not proved it durable.

I also agree that the CNY 9.341 billion investing outflow, 37.8% liability growth, and unreconciled September financing prevent a confident per-share valuation. The CNY 12.184 billion cash balance and CNY 7.223 billion current-asset surplus give BILI room to investigate those questions; they do not answer them. Likewise, advertising, services and games offer potential ways to monetize its video community, but without current segment and engagement data I cannot claim those opportunities are already delivering.

So why take any position at the October 2 close of $14.44? To gain limited exposure to a business that has crossed from an operating loss into profit while growing revenue—not because $14.44 is demonstrably cheap or the chart has turned. Your wait-for-proof approach is reasonable. Mine remains a small, speculative BILI starter position for a risk-tolerant, long-horizon investor, with no increase until 2026 margins, cash flow and financing terms check out. Price below the $15.82 daily trend line and $16.53 falling 50-day average demands that restraint; a close below $14.31 would warrant reassessment, not a cents-away mechanical stop.

Bear Researcher

Bear Analyst: Bull, I agree that BILI’s 2025 turnaround was real. Revenue grew, operating income turned positive, and cash from operations improved. My objection is to paying for that improvement as though it has already proved durable in 2026. The supplied financial data give us no usable 2026 income or cash-flow comparison.

The margin leaves little room for disappointment. BILI earned CNY 1.124 billion in operating income on CNY 30.348 billion of revenue—an operating margin of about 3.7%. At that revenue level, a return from 2025’s 36.6% gross margin to 2024’s 32.7% would reduce gross profit by roughly CNY 1.18 billion, more than the entire 2025 operating profit if other costs stayed unchanged. I’m not forecasting that reversal. I’m pointing out how much the bull case depends on sustaining recent gains while BILI competes for viewers, advertisers, and spending on its services and games. We lack current segment and engagement figures to show that it is winning those contests.

I also think “strong cash generation” needs a narrower definition. The CNY 6.634 billion free-cash-flow figure subtracts reported capex from operating cash flow; it does not encompass all investing activity. In 2025, CNY 7.147 billion of operating cash flow fell CNY 2.194 billion short of the CNY 9.341 billion total investing outflow, while financing cash flow was positive CNY 4.087 billion. We cannot tell from these totals what those transactions were or whether they will recur. That uncertainty matters alongside liabilities growing 37.8%, faster than cash, and cash covering only about 60% of current liabilities. Your liquidity point is fair—BILI had a CNY 7.223 billion current-asset surplus—but it is not a substitute for understanding those obligations.

September’s convertible-note and equity-placement headlines add another per-share question. The reported US$700 million pricing and US$500 million completion should not be added together, and neither dilution nor a repurchase offset can be quantified from the headlines. But until the terms are reconciled, I would not build a per-share upside case on a bank’s $23 target.

Finally, the market is asking for the same proof you are. At the October 2 close of $14.44, BILI was below its falling $16.53 50-day average and $15.82 daily SuperTrend line; its higher-priority weekly trend remained down. The completed monthly TD-9 setup makes a bounce plausible, not confirmed. A close below the $14.31 recent low would make the downside case stronger. I would not use a few social posts or a broad ADR headline as evidence of operating trouble—but I would not ignore the verified price weakness either.

So we agree on the diligence; we differ on the investment conclusion. For BILI, I would stay on the sidelines rather than buy the 2025 turnaround in advance of 2026 results, financing clarity, and a sustained improvement in the trend. Bear Analyst: Bull, I agree that BILI’s 2025 turnaround deserves attention. My disagreement is with buying even a small position before we know whether it survived into 2026. A smaller position limits exposure; it does not resolve uncertainty about margins, cash needs or per-share dilution.

Your growth scenario shows why I’m cautious. If BILI repeats 13.1% revenue growth but gross margin returns to 32.7%, gross profit rises only about CNY 0.1 billion from 2025. The roughly CNY 1.2 billion operating profit in your illustration depends on keeping the costs between gross and operating profit essentially flat while revenue grows. A roughly 12% increase in those costs would bring operating profit close to zero. That is a sensitivity test, not a forecast—but without current segment or engagement data, we cannot establish that advertising, services and games will deliver the growth and cost discipline your case requires.

Liquidity is real, but it is not the same as financial clarity. BILI’s CNY 12.184 billion cash balance and CNY 7.223 billion current-asset surplus are reassuring. Against that, liabilities grew 37.8% in 2025, cash covered only about 60% of current liabilities, and CNY 7.147 billion of operating cash flow did not cover CNY 9.341 billion of total investing outflows. We need to identify those outflows and reconcile September’s convertible and equity transactions before relying on historical cash generation in a per-share investment case. I would not presume dilution, but neither would I presume repurchases offset it.

The entry argument is weak, too. At $14.44 on October 2, BILI remained below its $15.82 daily trend line and falling $16.53 50-day average, with the weekly trend down. Exhaustion indicators make a bounce possible; they do not establish a turn. Nor does a bank’s $23 target tell us what BILI is worth without a current valuation and the financing terms.

So I would wait rather than start a staged BILI position. I want 2026 results showing that margins and operating cash flow persist, an explanation of investing and financing flows, and stronger price participation. A close below $14.31 would add to the downside case—not prove that the 2025 turnaround was false, but make paying for it in advance even harder to justify. Bear Analyst: Bull, I agree that a small position limits the dollars at risk. It does not answer the investment question: why buy BILI at $14.44 before we can assess its 2026 performance or the September financing on a per-share basis?

Your operating-leverage scenario is arithmetically plausible, but it is sensitive even without a return to 2024’s gross margin. If revenue grew another 13.1% and the costs between gross and operating profit rose 12%, holding gross margin at 36.6% would produce roughly CNY 1.4 billion of operating profit. Let gross margin slip by just one percentage point, to a level still well above 2024’s, and that profit falls to roughly CNY 1.0 billion—below 2025’s CNY 1.124 billion. Neither case is a forecast. The point is that strong sales growth alone may not deliver the earnings growth a buyer hopes for. The supplied data give us no usable 2026 segment or engagement figures to judge that trade-off against competition for viewers, advertisers and spending.

I give BILI full credit for CNY 7.147 billion of 2025 operating cash flow and its year-end liquidity. But those are historical figures. We still need to understand why total investing outflows exceeded operating cash flow by CNY 2.194 billion, what drove liabilities up 37.8%, and how the convertible offering, equity placement and repurchases affect each share. I am not asserting that the investing outflow will recur or that the financing is necessarily dilutive; I am saying neither uncertainty belongs in an unqualified upside case.

Waiting could mean missing the first part of a rebound. That is the cost of confirmation. For now, BILI remains below its $15.82 daily trend line and falling $16.53 50-day average, with the weekly trend down and no convincing improvement in OBV. The monthly exhaustion signal gives your starter-position idea a rationale, but not evidence that the turn has begun.

My recommendation remains to wait on BILI, rather than initiate even a small position. I would revisit it when current results demonstrate sustained margins and cash generation, the financing terms are reconciled, and price strength has better participation. A close below $14.31 would strengthen the near-term downside case; it is a warning level, not a guaranteed floor. Bear Analyst: Bull, I agree that BILI’s 2025 turnaround is more than a one-quarter promise. But it is still one profitable fiscal year, with no usable 2026 income or cash-flow comparison in the supplied data. And operating cash flow was already CNY 6.015 billion in 2024, when BILI reported an operating loss. Cash generation is valuable; by itself, it does not prove that the new operating profit will persist.

Your scenario also depends on growth staying strong. I accept that a 13.1% revenue gain could leave BILI profitable even with a modest margin slip and higher costs. But keep your illustrative 35.6% gross margin and 12% increase in costs between gross and operating profit, then slow revenue growth to 5%: operating profit falls to roughly CNY 0.15 billion, versus CNY 1.124 billion in 2025. That is not my forecast. It shows how quickly the apparent earnings cushion shrinks if growth moderates while spending rises. We have no current segment or engagement figures to establish that BILI can sustain growth against competition for viewers and advertisers without higher costs.

The CNY 12.184 billion year-end cash balance makes this a case for caution, not a claim of financial distress. Still, liabilities grew 37.8%, operating cash flow did not cover total investing outflows, and the September convertible, placement and repurchase terms remain unreconciled. Until those flows and their per-share effects are clear, we cannot tell whether $14.44 adequately compensates an investor for the risks. A small position limits the size of that unanswered bet; it does not improve its evidence.

Finally, BILI closed October 2 below its $15.82 daily trend line and falling $16.53 50-day average, with the weekly trend down. I agree that $14.31 is a warning reference, not a sensible cents-away stop in a stock with $0.46 ATR. The exhaustion signals warrant watching for a turn, but they do not show one yet.

I would wait rather than initiate BILI, even speculatively. I could miss the first leg of a rebound. In exchange, I want 2026 proof of sustained margins and cash flow, clarity on the financing, and stronger price participation before taking the risk. Bear Analyst: Bull, I accept your point: BILI’s 2025 turnaround was real, and your CNY 1.35 billion operating-profit scenario shows that slower growth need not mean a return to losses. But it also shows how narrow the margin for error is. At 5% revenue growth and a 35.6% gross margin, holding operating costs flat produces only about CNY 0.23 billion more operating profit than in 2025. An increase of roughly 2.3% in those costs would erase that improvement. The CNY 0.13 billion cost reduction achieved in 2025 is encouraging; one year of it is not enough to assume costs stay flat as BILI competes for viewers, advertisers and spending.

That is why I would not call a starter position a cheap way to test the thesis. It limits the dollars committed, but we still cannot judge whether $14.44 offers adequate compensation: the supplied statements give no usable 2026 income or cash-flow comparison, no current segment or engagement figures, and no reconciled per-share effect from September’s financing. I am not claiming the financing is dilutive or that the CNY 9.341 billion investing outflow will recur. I am saying those questions matter before putting a value on each BILI share—particularly after liabilities grew 37.8% in 2025.

The chart offers no reason to pay for that uncertainty early. BILI closed October 2 below its $15.82 daily trend line and falling $16.53 50-day average; the weekly trend is down, and OBV has declined overall since September 8. The monthly exhaustion setup makes a bounce possible, but it has not confirmed one. A close below $14.31 would strengthen the downside case, not establish a guaranteed floor.

I would wait rather than initiate BILI, even in small size. I could miss the first leg of a recovery. I would rather take that risk than buy before 2026 margins and cash flow, financing terms, and price participation give us a firmer basis for the investment.

Research Manager

Recommendation: Underweight

Rationale: For BILI, the bull is right that 2025 was a genuine turnaround: revenue grew 13.1%, operating income swung to CNY 1.124 billion, operating cash flow reached CNY 7.147 billion, and year-end cash and the current-asset surplus offer a liquidity cushion. But the bear's case carries more weight for committing capital now. The 2025 operating margin was only about 3.7%; there are no usable 2026 results or current segment/engagement data to establish durability. Total 2025 investing outflows exceeded operating cash flow by CNY 2.194 billion, liabilities rose 37.8%, and September financing's per-share effect remains unreconciled; the investing gap alone does not establish recurring cash burn. With no defensible current per-share valuation, and BILI at the last supplied $14.44 close below its $15.82 daily trend line and $16.53 falling 50-day average with weak participation, buying ahead of confirmation is less compelling than waiting. The liquidity and real operating progress temper the call to Underweight, not Sell.

Strategic Actions: For BILI, target no more than 50% of a standard allocation: trim an existing larger holding toward half size; if unowned, defer initiation rather than buying a speculative starter. Do not use the historical $14.31 low as a tight automatic stop; a close below it triggers a review of price action and fundamentals. Reassess for a move back toward a full standard allocation only after obtaining 2026 evidence of sustained margins and operating cash flow, explaining the investing outflows and liability growth, reconciling convertible/equity/repurchase terms per share, and seeing BILI reclaim $15.82 then $16.53 with better volume/OBV. Reduce further if profitability reverses or financing materially impairs per-share value. Price levels are from the supplied October 2 snapshot, not live quotes.

III. Trading Team Plan

Trader

Action: Sell

Reasoning: BILI’s Underweight plan calls for trimming holdings above half of a standard allocation, not initiating a new position. At the last supplied $14.44 close, BILI was below its $15.82 daily SuperTrend and falling $16.53 50-day average, while the higher-priority weekly trend remained down and OBV lacked rebound confirmation. The 2025 operating turnaround and liquidity cushion argue against exiting indiscriminately, but missing 2026 results and unresolved financing effects weaken the case for a full allocation. Treat a close below $14.31 as a review trigger, not an automatic stop; $0.46 ATR makes a nearby stop vulnerable to ordinary volatility.

Entry Price: not provided

Stop Loss: not provided

Position Sizing: If BILI is held above 50% of a standard allocation, trim toward 50%; if unowned, do not initiate. No position or portfolio information was provided.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision

Aggressive Analyst

Aggressive Analyst: I favor the proposed SELL for BILI, but the aggressive version is a selective trim, not a retreat. If BILI is above half of your standard allocation, cut it toward 50%. That releases capital from a weak trend while preserving meaningful exposure to the turnaround if a reversal arrives. If you do not own BILI, do not initiate it on this evidence.

The case for keeping that remaining stake is real. In 2025, BILI grew revenue 13.1%, moved from an operating loss to CNY 1.124 billion in operating profit, and generated CNY 6.634 billion of free cash flow as defined in the supplied report. Its monthly trend is still up, and the completed monthly TD-9 buy setup raises the possibility of selling exhaustion. A reflexive full exit could surrender a sharp recovery.

But a promising business is not, by itself, a reason to carry a full trading allocation. At the last supplied $14.44 close, BILI was below its $15.82 daily SuperTrend and falling $16.53 50-day average; the higher-priority weekly trend was also down. RSI at 36.98 and declining OBV do not confirm buyers taking control. The September financing terms remain unresolved in the supplied material, and these financial statements do not tell us whether the 2025 improvement continued through 2026. Selling the excess position makes room to pursue stronger opportunities, if available, without betting the entire BILI thesis on an unconfirmed bounce.

Neither the conservative nor the neutral analyst has made an argument yet, so I won’t put words in their mouths. My challenge to a full-exit view would be that it discounts BILI’s demonstrated operating progress and the value of retaining exposure through a possible exhaustion reversal. My challenge to a passive hold-or-add view would be that it asks us to ignore the weekly downtrend and weak participation just when sizing discipline matters most. The bolder choice is to demand evidence before restoring size, rather than let either fear or hope set the allocation.

I would not turn $14.31 into an automatic stop: it is only $0.13 below the last close, versus a $0.46 ATR. A close below it, especially with falling OBV, merits review. Conversely, a close above the then-current daily SuperTrend line—$15.82 in the supplied data—followed by stronger OBV and momentum would give BILI a credible case for rebuilding exposure. Until then, SELL the amount above half allocation and keep the remaining upside alive. Aggressive Analyst: Conservative Analyst, I agree that half a standard allocation is a ceiling, not a floor. If BILI already creates excessive China-linked exposure or breaches the trader’s loss budget, trim below half. But we have no portfolio data showing that it does. Treating a possible concentration problem as a reason to abandon an otherwise affordable residual stake would give up the upside of BILI’s turnaround without evidence that the risk budget requires it.

Your cash-flow concern deserves a closer distinction. BILI’s CNY 7.147 billion of 2025 operating cash flow did not cover its CNY 9.341 billion total investing outflow. But the supplied definition of free cash flow, which subtracts reported capital expenditure rather than all investing activity, was positive CNY 6.634 billion. We do not know what drove the rest of the investing outflow, just as we do not know the net per-share effect of September’s financing. Those are reasons to cap exposure and investigate, not evidence that operating cash generation collapsed. The CNY 12.184 billion year-end cash balance strengthens the case against an indiscriminate exit, though it does not erase the faster growth in liabilities.

Neutral Analyst, I accept your concentration test and your point that BILI’s monthly TD-9 buy setup is not a reversal signal. Where I would be bolder is in treating an affordable remaining stake as deliberate upside exposure, not merely a holding we have failed to sell. BILI’s weekly and daily trends are down and OBV has weakened; that is exactly why I support selling the excess now. Yet the monthly trend remains up, the monthly TD-9 setup is complete, and 2025 delivered both operating profit and cash generation. Demanding every fundamental and technical uncertainty be resolved before retaining any exposure risks missing a recovery. From the last supplied $14.44 close, the current $15.82 daily trend line is roughly 9.6% higher—an initial test, not a forecast or a reason to buy today.

I also agree with both of you that $14.31 is a review trigger, not a mechanical stop: it sits only $0.13 below that close against a $0.46 ATR. A close beneath it with falling OBV would call for a fresh decision, potentially another trim. Conversely, a close above the then-current daily trend line with improving participation would justify reassessing size while promptly checking the 2026 results and financing terms; I would not wait for every possible confirmation before even reconsidering the trade.

My recommendation remains SELL BILI holdings above 50% of a standard allocation toward that ceiling, and further if the actual portfolio risk budget requires it. If BILI is already a modest, affordable holding, do not sell mechanically; if unowned, do not initiate on the supplied evidence. That is the aggressive opportunity here: free capital from a weak trend without surrendering all exposure to a potentially valuable reversal. Aggressive Analyst: Conservative Analyst, you are right that half a standard allocation is a ceiling, not a promise that BILI fits the portfolio’s loss budget. But that test cuts both ways: without evidence of excessive concentration, uncertainty alone is not a case for selling an affordable residual stake. BILI’s 2025 revenue grew 13.1%, operating income turned positive, and defined free cash flow reached CNY 6.634 billion. Missing 2026 results prevent us from assuming that progress continued; they do not erase it.

Your balance-sheet concerns justify the SELL, not necessarily a full exit. BILI’s CNY 7.147 billion of operating cash flow did not cover CNY 9.341 billion of total investing outflow, but the outflow’s composition is unknown. Faster-growing liabilities and unreconciled September financing require investigation, not an assumption that operating cash generation failed or that dilution has a known size. Capping exposure while keeping some upside is the sharper response to those unknowns.

Neutral Analyst, I agree that the monthly TD-9 buy setup is not confirmation and that reclaiming the daily SuperTrend would only be an initial test. My challenge is to treating “initial” as unimportant. From the last supplied $14.44 close, the then-current $15.82 line was about 9.6% higher. Waiting for the weekly trend, every filing question, and participation all to resolve before reconsidering size could mean missing a substantial part of a recovery. The monthly trend remains up and the weekly TD count is nearing exhaustion, even though neither protects BILI from further losses. Those are reasons to preserve risk-budgeted optionality, not reasons to buy an unconfirmed bounce.

We agree that the weekly downtrend, falling OBV and price below the falling $16.53 50-day average make excess exposure unattractive now. Thin, mildly bearish social sentiment adds little conviction to either side, while reports of easing yields offer a possible growth-stock tailwind, not a BILI-specific catalyst. I would use a fresh quote and SELL BILI only to the extent holdings exceed 50% of a standard allocation, trimming further if correlated exposure or plausible losses breach the actual portfolio budget. If a smaller holding passes that test, retain it deliberately; if BILI is unowned, do not initiate on this evidence. A close below $14.31 with weakening OBV calls for review, not an automatic stop inside the $0.46 ATR. A reclaim of the then-current daily trend line with stronger participation would prompt a fresh sizing decision alongside checks of 2026 results and financing terms—not an automatic return to full size. Aggressive Analyst: Conservative Analyst, I agree that 50% of a standard allocation is a ceiling, not a default stake. A BILI position that breaches the trader’s loss budget or compounds China-linked exposure should be cut further. But the risk test should decide how much upside to retain, not assume that unresolved information makes every residual position unjustifiable. BILI’s 2025 revenue grew 13.1%, operating income swung to CNY 1.124 billion, and defined free cash flow reached CNY 6.634 billion. Those are historical results, not proof of 2026 performance—but they give an affordable holding a substantive turnaround thesis.

Your cash-flow and financing objections support trimming the excess now. BILI’s CNY 7.147 billion of operating cash flow did not cover its CNY 9.341 billion total investing outflow; we do not know the outflow’s composition. Liabilities grew faster than cash, and September’s net per-share financing effect is unresolved. None of that establishes that operating cash generation failed. Selling down to a risk-budgeted stake is a more discriminating response than treating the unknowns as a reason to forfeit all rebound exposure.

Neutral Analyst, you are right that the distance from the last $14.44 close to the then-current $15.82 daily SuperTrend line is not a guaranteed missed gain. My point is about opportunity cost, not a price forecast. The monthly trend remained up, the monthly TD-9 buy setup was complete, and the weekly count was nearing exhaustion. None confirms a reversal, but waiting for the weekly trend, participation, filings, and financing questions all to resolve before even reconsidering size could sacrifice the early part of one. A daily reclaim with stronger OBV should trigger a prompt sizing review, not an automatic purchase; current 2026 results and financing terms matter especially before materially rebuilding. Thin, low-confidence social sentiment cannot settle the debate, and easing yields are a possible tailwind, not a BILI catalyst.

My recommendation remains SELL BILI holdings above 50% of a standard allocation toward that ceiling, or lower if a portfolio-level loss and concentration test requires it. Keep a smaller holding only if it passes that test; if unowned, do not initiate on this evidence. Use a fresh quote. A close below $14.31 with weakening OBV warrants review, not a mechanical stop $0.13 below the last close when ATR was $0.46. That is the aggressive choice within this SELL decision: release capital from a weak weekly trend without automatically surrendering a risk-sized claim on a possible turnaround. Aggressive Analyst: Conservative Analyst, I agree that half an allocation has no automatic claim on capital. If BILI fails a portfolio stress test—including correlated China-linked exposure and a gap below the $13.37 monthly trend reference—sell more, potentially all of it. But requiring resolved 2026 results and financing terms merely to retain an affordable residual stake sets an entry-level burden of proof for an existing position. BILI’s 2025 revenue grew 13.1%, operating income reached CNY 1.124 billion, and defined free cash flow was CNY 6.634 billion. Those results do not establish 2026 performance, but neither does the unexplained CNY 9.341 billion investing outflow establish recurring operating deterioration. The unknowns argue for a smaller stake, not a presumed zero stake.

Neutral Analyst, the remaining exposure is certainly not a free option; that is why I would size it against a plausible gap loss rather than call 50% a target. Where I would press harder is on the cost of waiting. BILI’s monthly trend remains up, its monthly TD-9 buy setup is complete, and the weekly count is nearing exhaustion. None confirms a rebound, but an affordable residual position lets the trader participate if price improves before every filing and trend question is settled. Easing yields could help a growth-stock valuation, while weaker advertising demand or renewed inflation could offset that benefit; neither macro narrative is a BILI-specific buying signal. The thin, low-confidence bearish social sample is no reason to abandon the turnaround thesis either.

The weekly downtrend, weaker OBV, and October 2 close of $14.44 below the then-current $15.82 daily trend line and $16.53 falling 50-day average still make SELL the right action for excess exposure. Use a fresh quote: trim BILI above 50% of a standard allocation, go lower if the actual loss budget requires it, and do not initiate if unowned. A close below $14.31 with falling OBV calls for review, not a stop inside the $0.46 ATR. A daily trend reclaim with stronger participation should prompt a prompt sizing review—not an automatic add—while current 2026 results and financing effects are checked before materially rebuilding. That frees capital from a weak trend without needlessly surrendering every risk-budgeted claim on a recovery.

Conservative Analyst

Conservative Analyst: I agree with the Aggressive Analyst’s SELL direction for BILI, but I disagree that retaining a “meaningful” half allocation is automatically prudent. Half of a standard allocation is a ceiling for this plan, not a floor. Without portfolio information, it could still be too much if BILI adds to an existing concentration in China-linked growth stocks or exceeds the firm’s loss budget.

The turnaround is real, but it is not yet a reliable case for keeping that much exposure. BILI’s 2025 operating profit and cash generation are historical; the supplied statements do not show whether they persisted in 2026. Its CNY 7.147 billion of operating cash flow did not cover the CNY 9.341 billion total investing outflow, liabilities grew faster than cash, and the net per-share effects of September’s financing remain unresolved. Those gaps matter more to capital preservation than the possibility of missing a sharp bounce.

I also would not treat the monthly uptrend or completed TD-9 buy setup as protection for the remaining stake. At the last supplied $14.44 close, BILI was below its daily trend line and falling 50-day average, the higher-priority weekly trend was down, and OBV had not confirmed a rebound. The monthly $13.37 line is a regime-risk reference, not a downside floor. A close below $14.31 with weakening OBV should prompt a fresh risk assessment, not an automatic stop; a $0.13 stop from $14.44 is tighter than BILI’s $0.46 ATR.

The Neutral Analyst has not offered a position to rebut. My recommendation is to sell BILI holdings above 50% of a standard allocation, consider trimming further if portfolio concentration or the loss budget warrants it, and make no new purchase if unowned. Rebuilding should require current 2026 filings, clarified financing terms, and sustained price and participation improvement—not exhaustion signals alone. Conservative Analyst: Aggressive Analyst, I agree with selling the excess BILI position, but I would not describe the remaining half allocation as deliberate upside exposure until it passes a portfolio risk test. We do not know the firm’s holdings or loss budget, so we cannot call that stake affordable. The 2025 turnaround and CNY 6.634 billion of defined free cash flow are genuine positives, but neither establishes 2026 performance. Operating cash flow did not cover BILI’s total 2025 investing outflow; that does not prove operating deterioration, but the outflow’s composition, faster-growing liabilities, and unresolved September financing terms all limit our confidence in the balance-sheet and per-share outlook.

Neutral Analyst, I agree that those unknowns do not justify an automatic full exit, and the thin social-sentiment sample should not decide the trade. But “modest” must mean modest relative to potential loss and correlated China-linked exposure, not simply less than half a standard allocation. The case for retaining BILI is still vulnerable: at the last supplied $14.44 close, the higher-priority weekly trend was down, price was below the daily trend line and falling 50-day average, and OBV had not confirmed a rebound. The monthly uptrend and TD-9 setup are reasons to watch, not protection against further losses.

My recommendation remains SELL BILI holdings above 50% of a standard allocation, then reduce further—including exiting—if a review of concentration, plausible downside, and the firm’s loss budget warrants it. If an existing smaller holding passes that test, do not sell it mechanically; if BILI is unowned, do not initiate. A close below $14.31 with weakening OBV calls for reassessment, not an automatic stop so close to the last price relative to the $0.46 ATR. Before rebuilding, verify current 2026 results and financing terms, then look for sustained price and participation improvement rather than paying for a hoped-for recovery. Conservative Analyst: Aggressive Analyst, the absence of portfolio data does not establish that a half allocation in BILI is affordable. I agree that BILI’s 2025 turnaround should not be dismissed, and the unknown composition of its investing outflow does not prove operating cash generation deteriorated. But CNY 7.147 billion of operating cash flow did not cover CNY 9.341 billion of total investing outflow. Faster-growing liabilities, unavailable 2026 results, and unreconciled September financing leave too much unresolved to treat a half allocation as a default stake.

I also accept that waiting for confirmation could mean missing part of a BILI rebound. That is a real cost of caution, but not a reason to size for upside before measuring potential loss. At the supplied levels, reclaiming the $15.82 daily trend line would be an initial improvement while the weekly trend remained down and OBV had not confirmed sustained buying. The monthly uptrend and TD-9 setup make a reversal worth watching; neither limits the downside.

Neutral Analyst, I agree that BILI’s positive defined free cash flow and year-end cash balance argue against an automatic full exit. My concern is what qualifies as an “affordable” smaller holding. It must pass a loss-budget test that accounts for correlated China-linked exposure and a possible gap below the $13.37 monthly regime reference, which is not a price floor. Thin social sentiment and a broad lower-yield rally cannot settle that test or substitute for current company results.

I support the conditional SELL for BILI: use a fresh quote, trim holdings above 50% of a standard allocation, and reduce further—including exiting—if the actual portfolio risk test requires it. If a smaller holding passes that test, do not sell it mechanically; if unowned, do not initiate. A close below $14.31 with weakening OBV warrants prompt reassessment, not an automatic stop only $0.13 below the last $14.44 close against a $0.46 ATR. Before rebuilding, verify 2026 performance and financing effects, then require sustained improvement in price and participation. Conservative Analyst: Aggressive Analyst, I agree that BILI’s 2025 turnaround gives a risk-budgeted holding a thesis. But it does not give a half allocation a default claim on capital. We lack usable 2026 operating results, the composition of BILI’s CNY 9.341 billion investing outflow, and reconciled terms for September’s financing. None proves deterioration or dilution of a particular size; together, they make the potential loss harder to bound. BILI’s year-end cash is a cushion, but liabilities grew faster than cash. The burden of proof should be higher before retaining substantial exposure, not just before adding to it.

Neutral Analyst, I agree that an affordable small BILI holding need not be sold mechanically. “Affordable,” though, must account for a gap through the $13.37 monthly trend reference, correlated China-linked holdings, and the firm’s actual loss limit—not merely the fact that the holding is below half an allocation. The $13.37 line is not a floor. Likewise, positive defined free cash flow in 2025 does not resolve why operating cash flow fell short of total investing outflows or whether the turnaround persisted in 2026.

The opportunity cost of missing an early BILI rebound is real, but the evidence does not yet justify sizing around it. At the October 2 close of $14.44, BILI remained below its daily trend line and falling 50-day average, with the primary weekly trend down and OBV lacking rebound confirmation. The monthly TD-9 setup warrants attention, not reliance; a daily trend reclaim would warrant review, not an automatic increase.

My adjustment to the proposed SELL is to use a fresh quote, trim BILI above 50% of a standard allocation, and treat 50% strictly as a maximum pending a portfolio-level stress and concentration check. Trim further, potentially to zero, if that check fails; retain a smaller holding only if it passes. Do not initiate BILI if unowned. A close below $14.31 with weakening OBV calls for prompt reassessment, not a mechanical stop inside the supplied $0.46 ATR. Require current 2026 results, clarified financing effects, and sustained price and participation improvement before materially rebuilding. Conservative Analyst: Aggressive Analyst, I agree that BILI’s 2025 turnaround supports considering a small residual holding. But the cost of missing an early rebound is not a reason to reserve half an allocation before measuring the potential loss. BILI’s primary weekly trend is down, OBV has weakened, and the monthly TD-9 setup signals possible exhaustion, not downside protection. Even a reclaim of the then-current $15.82 daily trend line would be an initial test, not evidence that the larger risk has passed.

Neutral Analyst, you are right that the unexplained investing outflow does not prove recurring operating deterioration, and positive defined free cash flow argues against an automatic full exit. It also does not settle how much BILI is safe to retain. In 2025, operating cash flow fell CNY 2.194 billion short of total investing outflows, liabilities grew faster than cash, and cash covered a smaller share of current liabilities than a year earlier. The supplied data do not establish whether the turnaround continued in 2026 or resolve September’s financing effects. Year-end cash is a cushion, not a limit on shareholders’ losses.

My low-risk adjustment is to use a fresh quote and SELL BILI holdings above 50% of a standard allocation, treating 50% strictly as a ceiling. Stress-test the remainder against correlated China-linked holdings and a plausible gap below the $13.37 monthly reference, which is not a floor. Trim further or exit if that loss exceeds the portfolio budget; retain a smaller holding only if it passes. If BILI is unowned, do not initiate. A close below $14.31 with weakening OBV warrants prompt reassessment, not a mechanical stop within the supplied $0.46 ATR. Before materially rebuilding, verify current 2026 results and financing terms and require sustained price and participation improvement.

Neutral Analyst

Neutral Analyst: Aggressive Analyst, I agree with trimming BILI rather than making an all-or-nothing bet, but I would challenge the idea that half an allocation is automatically a sensible stake to retain. If BILI already overlaps heavily with other China-linked growth holdings, even half may exceed the portfolio’s loss budget. The completed monthly TD-9 setup suggests possible selling exhaustion, not a confirmed reversal; BILI’s weekly trend and OBV still argue against treating a rebound as established.

Conservative Analyst, I agree that missing 2026 results and unresolved financing terms justify restraint. But the CNY 9.341 billion investing outflow cannot yet be treated as recurring operating deterioration: its composition is unknown, while BILI generated CNY 6.634 billion of defined free cash flow in 2025 and held CNY 12.184 billion in cash at year-end. Those facts do not prove the turnaround continued, but they make an automatic full exit harder to justify. The mildly bearish social snapshot is too thin to settle the question either.

My moderate recommendation is to keep the proposed SELL conditional on position size: if BILI exceeds half a standard allocation, trim it to no more than half, and trim further if concentration or the loss budget requires it. If it is already a modest, affordable holding, do not sell mechanically; if unowned, do not initiate on this evidence. A close below $14.31 with weakening OBV calls for review, not an automatic stop—it is only $0.13 below the last supplied $14.44 close, versus a $0.46 ATR. Before rebuilding, seek current 2026 results and financing terms alongside sustained price and participation improvement above the then-current daily trend line, rather than relying on exhaustion signals or a broad market rally. Neutral Analyst: Aggressive Analyst, I agree with selling excess BILI exposure, but I would push back on calling the remaining half allocation “deliberate upside exposure” before checking what it could cost the portfolio. Half is a ceiling, not a target. BILI’s monthly uptrend and completed TD-9 setup make a rebound plausible, but the weekly trend is down, OBV has weakened, and a move above the then-current $15.82 daily SuperTrend line would be an initial test—not, by itself, a reason to restore size.

Conservative Analyst, your risk test is essential, but I would not let unresolved information become an argument for exiting every affordable holding. BILI produced operating profit and CNY 6.634 billion of defined free cash flow in 2025. Its CNY 9.341 billion total investing outflow deserves investigation, yet its unknown composition does not establish that operating cash generation deteriorated. Equally, the year-end cash balance is a cushion, not proof that faster-growing liabilities or September’s financing have no cost to shareholders. A small position that passes a realistic loss and concentration test can preserve upside while those questions are checked.

My recommendation remains a conditional SELL: trim BILI above 50% of a standard allocation to no more than that level, and go lower if correlated China-linked exposure or plausible losses exceed the portfolio’s budget. Do not mechanically sell a smaller holding that passes that test, and do not initiate if unowned. Use a fresh quote before acting; $14.44 is the October 2 close, not a live price. A close below $14.31 with falling OBV warrants reassessment, not an automatic stop just $0.13 below that close against a $0.46 ATR. Before materially rebuilding, seek current 2026 results, clarified financing effects, and sustained improvement in price and participation. Lower yields could help BILI’s valuation, but weaker advertiser demand or renewed inflation could offset that benefit. Neutral Analyst: Aggressive Analyst, I agree that retaining some BILI can preserve upside, but the roughly 9.6% distance from the last $14.44 close to the then-current $15.82 daily trend line is not a gain an investor is guaranteed to miss. BILI could fall further before testing that moving line. I would call a residual stake “affordable” only after accounting for correlated China-linked holdings and a plausible gap below the $13.37 monthly reference, which is not a price floor. Half an allocation is a ceiling, not a target.

Conservative Analyst, that risk test need not become a requirement to exit every small BILI holding until all uncertainty disappears. BILI’s 2025 operating profit and CNY 6.634 billion of defined free cash flow are meaningful evidence of progress. The CNY 9.341 billion total investing outflow and faster-growing liabilities demand investigation, but the outflow’s unknown composition does not prove recurring operating deterioration. A position that passes the portfolio’s loss budget can retain upside while the missing 2026 results and September financing effects are checked.

My recommendation remains a conditional SELL: using a fresh quote, trim BILI above 50% of a standard allocation to no more than that ceiling, and trim further—including exiting—if concentration or plausible losses exceed the actual budget. Do not mechanically sell a smaller holding that passes that test; if unowned, do not initiate. A close below $14.31 with weakening OBV merits reassessment, not an automatic stop just $0.13 below the last close versus a $0.46 ATR. A reclaim of the then-current daily trend line with stronger participation would justify reconsidering size, not automatically restoring it. Material rebuilding should also depend on current 2026 results and clarified financing terms. Lower yields might help BILI’s valuation, but weaker advertising demand or renewed inflation could offset that benefit. Neutral Analyst: Aggressive Analyst, I agree that BILI’s 2025 operating turnaround gives a small residual holding a reason to exist. But that upside is not a free option: the supplied data do not show whether profits persisted in 2026 or what September’s financing means per share. The monthly TD-9 setup and a possible daily trend reclaim justify attention, not a commitment to keep half an allocation regardless of portfolio risk.

Conservative Analyst, I agree that BILI needs a concentration and loss-budget check. I would not turn that caution into a default full exit, though. The CNY 9.341 billion investing outflow needs explaining, but its unknown composition does not negate BILI’s CNY 6.634 billion of defined 2025 free cash flow. Waiting for every uncertainty to disappear could also forfeit a risk-sized position through a recovery.

My recommendation is a conditional SELL for BILI: use a fresh quote, trim any holding above 50% of a standard allocation, then size the remainder against the portfolio’s loss budget and other China-linked exposure. Fifty percent is a ceiling, not a target; a smaller holding that passes that test need not be sold, while an unowned position should not be initiated on this evidence. Stress-test for a gap below $13.37 rather than treating that moving line as a floor. A close below $14.31 with weakening OBV calls for review, not an automatic stop within the supplied $0.46 ATR. Reconsider adding only as price and participation improve, alongside checks of current 2026 results and financing terms. Lower yields may help BILI’s valuation, but weaker advertising demand or renewed inflation could offset that benefit. Neutral Analyst: Aggressive Analyst, retaining some BILI exposure can be sensible, but the cost of waiting for confirmation is uncertain, while the risk of holding is real. The monthly TD-9 setup may signal selling exhaustion; it does not offset BILI’s down weekly trend or weaker OBV. I would not reserve half an allocation for a rebound before checking the portfolio’s China-linked concentration and the loss it could absorb in a gap below the $13.37 monthly reference.

Conservative Analyst, that risk check should not become a demand for complete certainty before keeping any BILI. Its 2025 operating profit and CNY 6.634 billion of defined free cash flow give a small holding a credible thesis. Operating cash flow fell short of total investing outflows, but the unexplained composition of those outflows does not establish recurring operating deterioration. Nor does the year-end cash balance settle the faster growth in liabilities or September’s financing effects.

My recommendation remains a conditional SELL for BILI. Using a fresh quote and actual portfolio exposures, trim holdings above 50% of a standard allocation to no more than that ceiling; trim further, including to zero, if a plausible gap loss or correlated holdings breach the loss budget. An existing smaller position that passes that test need not be sold mechanically. If BILI is unowned, do not initiate on the supplied evidence. A close below $14.31 with falling OBV calls for reassessment, not an automatic stop inside the supplied $0.46 ATR. A reclaim of the then-current daily trend line with stronger participation would justify reviewing size, while material rebuilding should also depend on current 2026 results and clarified financing terms.

V. Portfolio Manager Decision

Portfolio Manager

Rating: Underweight

Executive Summary: Underweight BILI over the next 1–3 months: with a fresh quote, trim any holding above 50% of a standard allocation to no more than that ceiling, and reduce further if China-linked concentration or a plausible gap loss breaches the portfolio’s risk budget. Retain a smaller, affordable existing holding rather than selling mechanically; if BILI is unowned, defer initiation. Treat a close below $14.31 with weakening OBV as a prompt to reassess, not an automatic stop, and stress-test a gap below the $13.37 monthly trend reference.

Investment Thesis: The analysts’ conditional SELL proposal is a trim of excess BILI exposure, which maps to Underweight rather than an indiscriminate full exit. BILI’s 2025 revenue rose 13.1%, operating profit reached CNY 1.124 billion and defined free cash flow was CNY 6.634 billion, supporting an affordable residual holding. Yet its operating margin was only about 3.7%, usable 2026 results and September financing’s per-share effects are unavailable, liabilities grew 37.8%, and CNY 7.147 billion in operating cash flow fell CNY 2.194 billion short of total investing outflows; the composition of those outflows is unknown and does not establish recurring cash burn. At the verified October 2, 2026 close of $14.44, BILI was below its $15.82 daily trend line and falling $16.53 50-day average; its higher-priority weekly trend was down and OBV offered no rebound confirmation. The monthly uptrend and completed TD-9 setup warrant watching for exhaustion, not buying it. No defensible valuation objective is supplied, so the technical downside target is the then-current $13.37 monthly SuperTrend reference: $14.44 − $13.37 = $1.07, or about 7.4% downside. That moving reference is neither a price floor nor a precise forecast. Reconsider materially increasing BILI only with sustained margins and operating cash flow in current 2026 filings, clarified investing and financing terms, and a reclaim of the then-current daily trend line followed by the 50-day average with stronger participation.

Current Price: 14.44

Price Target: 13.37

Confidence: Medium

Time Horizon: 1–3 months